Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

Patent metadata

Field	Value
Publication number	US-9243068-B2
Application number	US-201414310848-A
Country	US
Kind code	B2
Filing date	Jun 20, 2014
Priority date	Jun 25, 2013
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

First claim

What is claimed is:

1. A method comprising administering to a subject with cancer an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), and an effective amount of an antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade;
wherein the cancer is a solid tumor, and wherein SEMA4D is expressed by tumor cells of the solid tumor or by cells in the tumor microenvironment; and
wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NO: 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NO: 14, 15, and 16, respectively, and the antibody that inhibits the immune checkpoint blockade inhibitor is an anti-Programmed Cell Death 1 (PD-1) antibody, an anti-Programmed Death-Ligand 1 (PD-L1) antibody, an anti-Lymphocyte Activation Gene 3 (LAG3) antibody, an anti-B7-H3 antibody, an antigen-binding fragment thereof, or a combination thereof, or
wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising SEQ ID NO:9 and a variable light chain (VL) comprising SEQ ID NO:17, and the antibody that inhibits the immune checkpoint blockade inhibitor is an anti-cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) antibody, an anti-Programmed Cell Death 1 (PD-1) antibody, an anti-Programmed Death-Ligand 1 (PD-L1) antibody, an anti-Lymphocyte Activation Gene 3 (LAG3) antibody, an anti-B7-H3 antibody, an antigen-binding fragment thereof, or a combination thereof.

2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D interaction with its receptor.

3. The method of claim 2 , wherein the receptor is Plexin-B1.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D inhibits SEMA4D-mediated Plexin-B1 signal transduction.

5. The method of claim 1 , wherein the cancer is selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, esophageal cancer, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, head and neck cancer, and a combination thereof.

6. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and the antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade are administered separately or concurrently.

7. The method of claim 1 , wherein the subject has an elevated level of B cells, T cells or both B cells and T cells when compared to other cancer subjects.

8. The method of claim 7 , wherein the level of B cells and/or T cells per microliter of blood in the subject is about 1.5 times to about 5 times the mean number of B cells and/or T cells in circulation in other cancer patients.

9. The method of claim 7 , wherein the level of B cells and/or T cells per microliter of blood in the subject ranges from about 147 to about 588 and from about 1173 to about 3910, respectively.

10. The method of claim 1 , wherein the subject has B cell and/or T cell levels that fall within or above the range of B cells and/or T cells of healthy, non-cancer patients.

11. The method of claim 10 , wherein the B cell and/or T cell levels per microliter of blood in the subject range from about 225 to about 275 or more and from about 1350 to about 1650 or more, respectively.

Assignees

• Vaccinex Inc

Inventors

• Evans Elizabeth E
• Smith Ernest S
• Zauderer Maurice

Classifications

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title